CDC25C
Cell Division Cycle 25C Phosphatase
Gene Information Card
| Symbol | CDC25C |
|---|---|
| Full Name | Cell Division Cycle 25C |
| Gene Type | protein-coding |
| Chromosomal Location | 5q31.2 |
| NCBI Gene ID | 995 ncbi.nlm.nih.gov/gene/995 |
| Ensembl ID | ENSG00000158402 |
| UniProt ID | P30307 |
| OMIM ID | 157680 |
| HGNC ID | 1727 |
| Aliases | CDC25, CDC25C2, M-phase inducer phosphatase 3 |
Description
CDC25C is a protein-coding gene that encodes a member of the CDC25 family of dual-specificity phosphatases. The encoded protein activates the cyclin-dependent kinase CDC2 (CDK1) by removing inhibitory phosphate groups at Thr14 and Tyr15, thereby promoting G2/M phase transition of the cell cycle. CDC25C is regulated by phosphorylation and subcellular localization, and is a key target of the DNA damage checkpoint pathway. Aberrant expression or mutation of CDC25C is implicated in various cancers and cell cycle dysregulation.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Overexpression of CDC25C leads to premature CDK1 activation and uncontrolled cell proliferation | COSMIC; PMID: 12592315 |
| Colorectal cancer | Elevated CDC25C mRNA and protein levels correlate with poor prognosis and tumor progression | COSMIC; PMID: 15342611 |
| Non-small cell lung cancer | CDC25C overexpression associated with increased proliferation and resistance to chemotherapy | COSMIC; PMID: 16951146 |
| Prostate cancer | CDC25C upregulation promotes G2/M transition and tumor growth | COSMIC; PMID: 19029980 |
| Ovarian cancer | CDC25C overexpression linked to aggressive disease and reduced survival | COSMIC; PMID: 19654371 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 12.5 | Medium |
| Lymph node | 8.3 | Medium |
| Bone marrow | 6.1 | Low |
| Spleen | 5.4 | Low |
| Thymus | 4.8 | Low |
| Other tissues | <3.0 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa (cervical carcinoma) | 15.2 | High expression |
| MCF7 (breast cancer) | 10.1 | Medium expression |
| A549 (lung cancer) | 8.7 | Medium expression |
| HCT116 (colorectal cancer) | 7.3 | Low expression |
| K562 (leukemia) | 5.6 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.473C>T (p.Thr158Ile) | Missense | <0.1% | Unknown functional effect; reported in COSMIC |
| c.826G>A (p.Glu276Lys) | Missense | <0.1% | Unknown functional effect; reported in COSMIC |
| c.1003C>T (p.Arg335Trp) | Missense | <0.1% | Unknown functional effect; reported in COSMIC |
| c.1138G>A (p.Gly380Arg) | Missense | <0.1% | Unknown functional effect; reported in COSMIC |
Mutation functional classification
Loss of Function (LOF)
No well-characterized loss-of-function mutations reported in CDC25C. Most mutations are rare missense variants of unknown significance.
Gain of Function (GOF)
Overexpression of wild-type CDC25C is observed in multiple cancers, but specific gain-of-function mutations have not been clearly identified.
Dominant Negative (DN)
No dominant-negative mutations have been described for CDC25C.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Cell Cycle (KEGG hsa04110)
• p53 signaling pathway (KEGG hsa04115)
• G2/M DNA damage checkpoint (Reactome R-HSA-69481)
• Regulation of mitotic cell cycle (Reactome R-HSA-453274)
• CDK-mediated phosphorylation and removal of Cdc6 (Reactome R-HSA-69017)
Protein Summary
CDC25C is a dual-specificity phosphatase (UniProt P30307) that activates CDK1 by dephosphorylating Thr14 and Tyr15, essential for G2/M transition. The protein contains a N-terminal regulatory domain with multiple phosphorylation sites (e.g., Ser216) that control its activity and localization. During interphase, CDC25C is predominantly cytoplasmic; upon mitotic entry, it is phosphorylated and translocates to the nucleus. CDC25C is a target of the CHK1/CHK2 kinases in response to DNA damage, leading to its inhibition and cell cycle arrest. Overexpression of CDC25C is oncogenic and associated with poor prognosis in several cancers.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CDC25C Knockout HEK293 Cell Line | EDJ-KQ3163 | Human | 995 | Details Get a Quote |
| CDC25C Knockout A-549 Cell Line | EDJ-KQ24571 | Human | 995 | Details Get a Quote |
| CDC25C Knockout HCT 116 Cell Line | EDJ-KQ24572 | Human | 995 | Details Get a Quote |
| CDC25C Knockout HeLa Cell Line | EDJ-KQ24573 | Human | 995 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
